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Abstract: AIMS: Although rare, malignant sarcomatoid breast tumours without evidence of epithelial dif-
ferentiation comprise a diagnostic challenge with management implications. Earlier studies have generally
considered these to be primary breast sarcomas; however, supporting evidence is lacking and manage-
ment remains variable. This study aimed to provide an evidence-based approach to improve consistency
of diagnosis and management for such cases. METHODS AND RESULTS: A large series (n=140) of
metaplastic breast carcinoma (MBC) diagnosed in Nottingham over 18 years was analysed. Only cases
with available data on immunohistochemical expression of cytokeratins (CKs) were included. The preva-
lence and pattern of expression for various CKs were assessed and details of tumours negative for CKs
were collected. A diagnostic approach based on our experience is provided. 47 cases (34%) showed foci
of conventional type invasive breast carcinoma or DCIS, whereas 93 cases (66%) were diagnosed as MBC
based on morphology and/or CK expression. 97 cases (69%) were negative for one or more CKs, with
18 cases (13%) negative for 5 or more CKs. 8 cases (6%) lacked expression of all CKs tested. Further
examination showed evidence of carcinomatous nature in 5 cases, whereas 3 were diagnosed as MBC
following extensive diagnostic workup and on our experience. CONCLUSION: This study suggests that
MBC represent a spectrum of neoplasms with some lacking CKs expression. Sarcomatoid neoplasms of
the breast lacking evidence carcinomatous morphology and CK expression may represent an extreme end
of differentiation that can be considered as carcinomas rather than sarcomas for management purposes
(following extensive workup).
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ABSTRACT
AIMS: Although rare, malignant sarcomatoid breast tumours without evidence of 
epithelial differentiation comprise a diagnostic challenge with management implications. 
Earlier studies have generally considered these to be primary breast sarcomas; however, 
supporting evidence is lacking and management remains variable. This study aimed to 
provide an evidence-based approach to improve consistency of diagnosis and 
management for such cases. 
METHODS AND RESULTS: A large series (n=140) of metaplastic breast carcinoma 
(MBC) diagnosed in Nottingham over 18 years was analysed. Only cases with available 
data on immunohistochemical expression of cytokeratins (CKs) were included. The 
prevalence and pattern of expression for various CKs were assessed and details of 
tumours negative for CKs were collected. A diagnostic approach based on our 
experience is provided. 47 cases (34%) showed foci of conventional type invasive breast 
carcinoma or DCIS, whereas 93 cases (66%) were diagnosed as MBC based on 
morphology and/or CK expression. 97 cases (69%) were negative for one or more CKs, 
with 18 cases (13%) negative for 5 or more CKs. 8 cases (6%) lacked expression of all 
CKs tested. Further examination showed evidence of carcinomatous nature in 5 cases, 
whereas 3 were diagnosed as MBC following extensive diagnostic workup and on our 
experience. 
CONCLUSION: This study suggests that MBC represent a spectrum of neoplasms with 
some lacking CKs expression. Sarcomatoid neoplasms of the breast lacking evidence 
carcinomatous morphology and CK expression may represent an extreme end of 
differentiation that can be considered as carcinomas rather than sarcomas for 
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INTRODUCTION 
Metaplastic carcinoma of the breast (MBC) is a rare type of BC accounting for 0.5-3% of 
cases1,2. This comprises a heterogeneous group of tumours4,5 characterized by 
differentiation of the neoplastic epithelium towards squamous or mesenchymal 
elements6-14. The diagnosis of adenosquamous carcinoma and mixed squamous and 
spindle cell carcinomas as MBC is typically straightforward; in particular, when in situ 
carcinoma is present or when positivity of breast related immunohistochemical markers is 
seen. MBC with mesenchymal differentiation comprises tumours mostly with spindle cells 
although more rarely they demonstrate osseous, chondroid, rhabdoid or even neuroglial 
differentiation15.  Morphologically these sarcomatoid MBCs overlap with a variety of 
lesions including high-grade mesenchymal-looking tumours such as primary16 and 
metastatic sarcomas, stromal-rich phyllodes tumour, lymphomas and melanomas. 
Distinguishing MBC from these mimics may be challenging and is based on a 
constellation of features including clinical context, morphological appearances and 
immunohistochemical (IHC) / molecular features2,12,14,17-19. Morphologically these tumours 
are diagnosed as MBC if there is an associated conventional mammary carcinomatous 
element (either in situ lesions or conventional type invasive breast carcinomas) or by IHC 
demonstration of epithelial differentiation (i.e. the presence of cytokeratin (CK) positivity). 
Pathologists typically rely on a panel of IHC markers to demonstrate the epithelial nature 
of sarcomatoid breast neoplasms lacking definite morphological evidence of a breast 
epithelial origin, and to exclude mimicking lesions. 
 Apart from the well-established subtypes of sarcoma in the breast, such as 
angiosarcoma and malignant phyllodes tumour, several studies have reported a large 
number of undifferentiated primary breast sarcomas, for example designated as breast 
malignant fibrous histiocytoma/pleomorphic sarcoma/sarcoma not otherwise specified, 
fibrosarcoma, myxofibrosarcoma – all of which are diagnoses of exclusion20-22. 
Primary breast NOS sarcomas are extremely rare malignant tumours that are purported  
to arise from the mesenchymal tissue of the breast and are considered as a diagnosis of 
exclusion16,23-27. Most of the published studies of primary breast NOS sarcomas have not 
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morphological evidence of carcinomatous differentiation and CKs negativity as criteria for 
their diagnosis16 and most of the studies have included relatively small numbers of cases 
with variable panels of IHC markers10,30-356,14. To highlight the inconsistency in diagnosis 
and the challenge associated with relying on CKs positivity in such situations some of 
these sarcomas were reclassified on review and using different sets of CKs. In a previous 
study of breast sarcomas27, 11 out of 36 cases (30%) were reclassified as MBC following 
additional  CKs staining. In a different series, 6 out of 27 cases (22%) initially categorised  
as primary malignant fibrous histiocytoma of the breast were reclassified as MBC after 
testing for a range of CKs21. 
Categorisation of such CK negative sarcomatoid tumours for management purposes 
often poses great challenges with lack of consensus diagnostic assignments of these 
patients into specific categories resulting in different treatment strategies in different 
centres. In this study we evaluated a large number of sarcomatoid breast neoplasms with 
available data on CKs expression, to determine the nature of those tumours that lacked 
evidence of epithelial differentiation, including a CKs negative phenotype. We also 
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MATERIALS AND METHODS
Cohort
This study included cases diagnosed at the Nottingham City Hospital, Nottingham 
between 2000 and 2018. Cases included breast lesions from patients managed locally in 
Nottingham and others referred for a second opinion for diagnosis. Criteria for inclusion 
were all cases diagnosed as MBC, including malignant spindle cell and pleomorphic cell 
lesions, matrix producing MBC and MBC not otherwise specified, all of which were 
diagnosed using the previously published criteria6,36, summarised in the algorithm 
described in Figure 6.
Cases that were not assessed for immunohistochemical markers of epithelial 
differentiation, namely CKs (Table 1), were excluded. Cases diagnosed as metastatic 
sarcoma or carcinoma, angiosarcoma or phyllodes tumours were also excluded. As a 
result, of the 160 MBCs identified in our database, 20 cases were excluded. The CKs 
which were used are (not all of them tested in each case): AE1/AE3, CK5, CK5/6, CK7, 
CK8, CK18, CK8/18, CK19, CAM5.2, MNF116, 34ßE12, CK20, CK17, CK14. Details 
related to p63 staining were not purposefully recorded except in individual cases.
Variables collected included histological subtype, presence of overt mammary 
carcinomatous elements and of associated ductal carcinoma in situ (DCIS), along with 
data on all CKs tested. Clinical history and details of the microscopic description of CKs 
negative tumours were reviewed. The available slides from all cases in this study were 
reviewed by a single observer (MM) and doubtful cases were discussed with a second 
observer (RM) to confirm the pattern of expression for CKs and the presence of any 
associated carcinomatous component. The slides of a subset of this cohort were 
reviewed as part of a previous study12 and the data was also available. Slides of other 
markers were not reviewed. Details related to p63 staining were not purposefully 
recorded except in individual cases. The clinicopathological variables were compared 
using contingency tables and chi-squared and Pearson’s correlation tests.  All 
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This study was approved by the Nottingham Research Biorepository (NRB) Access 
Committee under the biobank ethical approval REC reference: 10/H1008/72 (NRES 
Committee North West - Greater Manchester Central)   
RESULTS
This study included 140 MBCs with available CKs expression data. 25 cases (18%) 
showed foci of associated conventional invasive breast carcinoma, NST; 30 (21%) cases 
showed associated DCIS, and 8 cases (6%) showed both in situ and invasive 
components. The number of CKs examined with IHC per case ranged from 1 to 9 
(median 5) (Table 1). Most cases had 4-5 CKs (46%) performed; the number of cases 
positive for any one specific CK matched the number of cases with negative staining, 
suggesting that CKs sensitivity is variable. 88% of cases (118/140) showed expression of 
at least one CKs (range 1-8, median 3) but the expression was variable from diffuse 
strong to focal and weak (Figure 1).  The remaining 22 cases were negative for all CKs 
tested (Table 2). Of all the CKs examined per case, 69% (n=97) of tumours were 
negative in the sarcomatous component for at least one (Table 2a), including cases with 
or without an associated carcinomatous component (Table 2b).
There was a strong positive correlation between the number of negative CKs and the 
total number of CKs requested (r = 0.6, p<0.001), but a negative correlation with the 
number of positive CKs (r = -0.6, p<0.001), representative of the fact that the more 
puzzling cases were more thoroughly investigated. A significant correlation was also 
identified between the presence of an invasive breast, NST component or DCIS and the 
number or pattern of CKs expression (p<0.001), highlighting that cases without these 
elements required more comprehensive immunohistochemical analysis for a diagnosis to 
be rendered. It should also be noted, however, that cases with those components that 
were not subjected to IHC for CKs were excluded from the analysis. 
The most commonly used CKs were as follows: CK14: 72% (72 positive of 100 cases 
stained), CK5/6: 64% (65/102), AE1/AE3: 60% (43/68), MNF116: 60% (46/77) and 
CAM5.2: 59% (51/86). Although CK17 was rarely used, it was positive in 75% of 
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(2/6; 33%). 
CK-negative tumours:
22 cases (16%) were negative for all CKs tested of the 3-9 CKs per case (median=6; 
Table 1) with 18 tumours (13%) negative for all CKs when 5 or more CKs were used 
(Table 2). These 22 CKs negative tumours were spindle cell neoplasms, mainly 
pleomorphic sarcoma-like tumours, together with 3 cases of osteosarcoma-like, 1 
chondrosarcoma-like and 1 rhabdomyosarcoma-like malignancy. None were squamous 
cell carcinoma or adenosquamous carcinoma. These tumours uniformly displayed a 
triple-negative phenotype (oestrogen receptor (ER), progesterone receptor (PR) and 
HER2 negative).
Of these 22 CKs negative tumours, 12 had an associated carcinomatous component and 
were diagnosed as MBC based on this association. 10 had no identifiable carcinomatous 
elements in the primary tumours during initial examination, and these were diagnosed 
MBC following more extensive workup. Of these 10, one high grade sarcomatoid tumour 
was sent for a second opinion and on preparation of the case, deeper levels were carried 
out which showed scanty foci of DCIS; therefore, a final diagnosis of MBC was rendered. 
In another case, which was a low to intermediate grade spindled cell tumour, a focus of 
DCIS was seen on extra tissue sampled at a later date following discussion with an 
expert, after an initial diagnosis of malignant spindle cell lesion of uncertain nature.
Eight cases remained with no evidence of DCIS, conventional type breast carcinoma 
components or CK expression and no positivity for other markers characteristic of breast 
carcinoma, such as hormone receptors, GATA3, GCDFP-15 or HER2. The details of the 
8 cases that were diagnosed as MBC after our routine workup  are as follows: 
* Four patients had a history of previous breast carcinoma in the same breast and review 
of the previous slides showed similarity with the current malignant neoplasm. 
In one patient the primary tumour was MBC diagnosed 6 years previously with spindle 
cell and squamous components. The spindle cell component morphologically matched 
the current tumour (Figure 2). The second patient had a prior invasive breast carcinoma 









This article is protected by copyright. All rights reserved
the original report. The third patient presented with a mass following neoadjuvant 
chemotherapy for MBC. Although this excised lesion did not show evidence of epithelial 
differentiation or CKs expression, it was diagnosed as MBC because of its similarity to 
the original tumour seen on the core biopsy which was CKs positive. The fourth patient 
presented with axillary and disseminated metastases with a spindle cell morphology and 
no CKs expression; a previous fibromatosis-like MBC was identified with convincing CK 
expression for 4 markers. The axillary metastasis presented 3 years after the initial 
lesion, while the disseminated gastro-intestinal and paraspinal metastases developed 5 
years after the initial event (Figure 3).
* One patient presented with a well-defined ossifying lesion of the breast formed by 
osteoid trabeculae and focally loose stroma featuring a proliferation of bland fibroblast-
like cells that lacked expression for a wide range of CKs.  Foci of chondroid matrix at the 
centre of the lesion were seen.  The lesion was originally thought to be a florid reactive 
process with bone formation and was classified as ossifying fasciitis, which is regarded 
as a form of nodular fasciitis. Four years later, however, the patient developed a bone 
metastasis and the histology of the metastasis revealed a malignant neoplasm with 
chondroid and osseous differentiation. This was similar to the original tumour, but also 
showed additional atypical features with focal epithelial differentiation (carcinomatous 
morphology) in keeping with metastatic matrix producing MBC (Figure 4). The original 
diagnosis of the tumour was retrospectively reviewed and regarded as MBC, given the 
new evidence brought by the metastatic focus.
*In three cases, the final diagnosis of MBC was based on the balance of probability and 
after the exclusion of other entities. One presented with spindle cell areas admixed with 
chondroid and osteoid formation. The presence of all these elements transitioning from 
one to another is the very definition of MBC and the diagnosis was based on the typical 
morphology, despite the lack of CKs. One was a spindle cell malignant neoplasm, not 
otherwise specified (Figure 5), while the other case displayed highly pleomorphic cells in 
a variable collagenous to myxoid background. In these three cases, the diagnosis of 
MBC carcinoma was made in routine practice based on the balance of probability after 
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immunoprofiling (Figure 6). As this was a diagnosis of exclusion, details of the diagnostic 
workup and why the diagnosis of MBC was favoured for management purpose were 
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DISCUSSION 
The concept of CK negative MBC is typically difficult to prove for several reasons; firstly, 
there is a wide range of CKs immunostains available but not all are used consistently 
across histopathology departments; secondly, these cases are rare and, thirdly, CKs are 
not routinely employed (or necessary) to diagnose MBC when there is morphological 
evidence of epithelial mammary gland origin. The number of CKs IHC assays a pathology 
laboratory has available can be limited and may not cover the range expressed by such 
poorly differentiated tumours. There is accumulating evidence that breast carcinomas 
may variably lack expression of one or more CKs, and even when positive may show 
only focal expression, supporting the existence of MBCs that lose expression of a range 
of CKs. 16,18,31,34,37-39 Even in conventional no special type/ductal carcinomas of the 
breast, approximately 5% show no expression of low molecular weight CKs and more 
than 70% are typically negative for high molecular weight CKs40-42.  Leibl et al.34 studied 
20 sarcomatoid MBC and found that 2 (10%) lacked expression of all CKs whereas 6 
(30%) showed weak and/or focal CKs expression. Interestingly, these authors found that 
myoepithelial marker expression was frequent in these tumours and they concluded that 
CKs negative sarcomatous breast lesions should be designated as MBC provided that 
they express myoepithelial cell markers such as p63, CD10 or SMA34. In a subsequent 
study16 the same authors investigated 7 cases that had previously been diagnosed as 
primary mammary sarcomas using the same criteria and suggested that these mammary 
NOS-type sarcomas could represent the extreme sarcomatous end of MBCs, which is in 
line with our experience. In a similar study of 36 MBC, 4 (10%) lacked all CKs 
expression43. In a large study of MBC by McCart Reed 39, 12 of 166 MBC (7%) were 
negative for AE1/AE3 whereas 22% (28/126) and 26% (36/140) of the cases were 
negative for CK14 and CK5/6 respectively. Our study, in line with those above, provides 
further evidence that a significant proportion of MBCs (69%) fails to express one or more 
CKs in the sarcomatous component of the tumours and that a proportion of cases (16%) 
completely lack expression of the CKs that were utilised in the current study. Of those 22 
that lacked CK expression in the current study, 14 cases showed morphological evidence 
of carcinomatous differentiation in the primary tumours whereas 5 cases showed indirect 
evidence of the carcinomatous nature as demonstrated by comparison with previous 
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Even when CK expression was seen in the MBCs in this series, variable reactivity was 
identified, ranging from cases with diffuse CKs expression to heterogeneous CKs 
expression. Patterns included a CK positive conventional carcinomatous component 
admixed with CK negative MBC elements and MBC with both focal positive and negative 
mesenchymal-looking areas, as well as cases with total negativity for CKs. The 
carcinomatous nature of these CK negative malignant mesenchymal-looking elements 
was confirmed by association with conventional carcinomatous components in some 
cases. Most of these mixed cases were referred to us for a second opinion because the 
reporting pathologist had concerns about the nature of the CK negative components. In 
our practice, we consider these CK negative components to be part of MBC based on 
their co-existence with areas of carcinomatous nature, regardless of their lack of CKs 
expression. This approach has been recently endorsed by the WHO working group14. We 
also highlight in this study that MBCs that are initially CK positive may lose CK 
expression in recurrences and/or metastases, as well as cases that were defaulted to CK 
negative MBCs after extensive work-up. This is based on the findings that: 
1 - a proportion of conventional type invasive breast carcinomas can be negative for 
CKs40-42, and this proportion is higher in MBC2,1823,26,29,30,39-41;
2 - the biological behaviour of some of these tumours with available outcome data 
supports their breast carcinomatous nature with change of morphology or immunoprofile 
between primary and metastatic or recurrent tumours2; 
3 - the statistical probability of BC with one or more CKs negative phenotype versus 
primary breast NOS sarcomas favours MBC24,36;
4 - a history of previous malignancy should be excluded or, if a previous malignancy is 
documented, review of the previous slides should be performed to compare and exclude 
the possibility of the lesion representing recurrent or metastatic tumour;
4 - lack of definite morphological and/or molecular evidence of other histogenetically 
defined sarcomas. 
It is important to note that some sarcomas express CKs44 and their diagnosis in such 
circumstances is based on other morphological and/or molecular features. Thus, CK 
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carcinomatous or sarcomatous nature and in essence, at this end of the differentiation 
spectrum, we are often left with a diagnosis of exclusion. The diagnostic assays used in 
routine practice to investigate both soft tissue sarcomas and other tumours included in 
the differential diagnosis of these poorly differentiated breast lesions are not highly 
specific or sensitive; additional studies are required to investigate their presence in some 
breast cancers, and in particular the sarcomatoid variant of MBC. Next generation 
sequence (NGS) testing is performed in occasional cases, but the interpretation of these 
results remains of limited value, as further evidence that the various genetic alterations 
identified can distinguish specific tumours types remains to be confirmed 45. 
Beyond the academic interest in histogenesis, these cases comprise a diagnostic 
challenge with significant management implications. In a previous study we concluded 
that a range of malignant matrix-producing breast tumours were all variants of MBC.16 In 
the present study, we have highlighted the existence of additional CK-negative MBC and 
provided evidence that sarcomatous-looking neoplasms in the breast, whether matrix-
producing or spindle/pleomorphic cell neoplasms, may be diagnosed as MBC even in the 
absence of conventional evidence of mammary epithelial differentiation. Such a diagnosis 
of CKs negative MBC, however, must be rendered with caution and only after the careful 
exclusion of other specific entities. Although this is essentially a diagnosis of exclusion, 
the outcome of this diagnostic algorithm is establishing a final diagnosis of MBC rather 
than sarcoma, with its subsequent management implications. In such workup, the 
diagnosis of MBC must be considered in the clinical context, morphology, immunoprofile 
and, whenever possible, molecular profile of the lesion. Fibromatosis-like MBC is 
diagnosed with confidence when it looks like fibromatosis but shows positivity for CKs 
and p63. Other low to intermediate grade spindle cell MBCs are diagnosed when arising 
in a background of other mammary lesions such as papillomas or complex sclerosing 
lesion, (or it is associated with DCIS or conventional type mammary carcinoma) and is 
CK positive. Melanoma and lymphoma are excluded based on morphology, history and 
IHC. The subtype of sarcomas included in the differential diagnosis is based on 
morphological features of the lesions and those included in the differential diagnosis will 
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There is some clinical uncertainty whether MBC lacking evidence of epithelial 
differentiation should be treated as sarcoma and managed by specialised sarcoma 
teams31,46,47 or treated using the same principles as conventional invasive breast 
carcinoma, a dilemma that prompted this study. Most studies on what has been labelled 
“breast sarcoma” have included a mix of tumours, so a conclusion on the outcome and 
response to chemotherapy of specific subtypes is not possible (with the exception of the 
well-established phyllodes tumours and mammary angiosarcomas).25,28,48,50 For example, 
one previous study which set out to compare the outcome of “primary breast sarcomas” 
versus phyllodes tumours included 12 cases of carcinosarcoma (34%), currently 
considered as variants of MBC. In that series, lymph node metastasis was reported in 
11% of patients and adjuvant chemotherapy was offered to 63% 25. In the McCart Reed 
study, MBC that was negative for epithelial markers (AE1/AE3) showed an association 
with poorer outcome39. Similar to other types of breast carcinomas, poorly differentiated 
MBC that has only focal evidence of epithelial differentiation are associated with a worse 
prognosis than well differentiated MBC with bona fide evidence of mammary epithelial 
differentiation47. This supports the view that CKs negative MBC is not much different from 
MBC with focal evidence of epithelial differentiation - which is currently catalogued as 
MBC, regardless of its outcome pattern. 
Given the rarity of what is called primary breast sarcomas NOS, there are no prospective 
randomized trials to guide therapy; treatment principles have been derived from small 
retrospective case reviews and inferred from studies of soft tissue sarcomas in other 
locations. Some reports indicate that breast sarcomas may benefit from radiotherapy and 
chemotherapy.49 Although a poorer outcome has been reported in patients defaulted to a 
diagnosis of sarcoma, despite being offered chemotherapy, when compared to 
conventional type carcinomas, this may be the result of chemotherapy being given to 
patients with other unfavourable tumour features49,50. Conversely, at present MBC, 
regardless of its morphology or CK expression, is treated similarly to other triple-negative 
BC of similar grade and stage. We believe that MBC comprises a spectrum of lesions 
and the threshold to recommend chemotherapy should not be determined based on the 
presence of CK expression alone (e.g. MBC with focal CK positivity vs CK negative 
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behave differently from poorly differentiated MBC, and their likelihood of response (or 
not) to systemic chemotherapy, is lacking. Further studies are needed but these should 
be based on lesions diagnosed and classified using clearer definitions. 
 
Based on the findings of this study, and on our experience, we recommend classifying 
these tumours as MBC in surgical excision specimens following an extensive work-up 
protocol as described above. We usually recommend lymph node examination, for 
staging purposes, and that radiotherapy and chemotherapy should be considered akin to 
other grade-, stage- and receptor-matched MBC. These tumours are likely to be clinically 
aggressive and depriving patients of the potential benefits of available regimens for 
treatment may not be justified, regardless of their histogenesis, as this is mainly of 
academic interest. When attempting to diagnose these malignant tumours in a pre-
operative core biopsy, we recommend that the clinicians be alerted to the possible 
differential diagnoses. At present, we believe neoadjuvant chemotherapy should not be 
recommended in such CK negative malignant mesenchymal tumours diagnosed on core 
biopsies, until a definite diagnosis can be made on the surgical excision specimen. 
Granted, this is mostly a pragmatic approach guided by our experience with these lesions 
and further studies are required to produce the evidence needed for changing protocols.
The current study has some limitations. No outcome data is available in the cases 
included in the study. The use of historical data might introduce some bias as 
immunohistochemistry protocols have evolved over time and the cytokeratin stains have 
been used with variable frequency. Ideally, a panel of cytokeratin stains should have 
been performed uniformly on this large series to overcome any potential bias, but the 
availability of tissue blocks precluded such an option. In addition, other markers to 
confirm the diagnosis such as GCDFP-15, mammaglobin, SOX10, SATB2 and S100 
were not routinely performed all cases. p63 stains were available in a subset of cases 
during the histological review process.
In conclusion, this study provides evidence that BC can show extensive mesenchymal 
differentiation and lose evidence of epithelial differentiation including the expression of a 









This article is protected by copyright. All rights reserved
diagnosed and managed as poorly differentiated MBC. 
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No of positive cases No. of negative cases 
Percent of 
positivity (%) 
CK5/6 55 33 63 
CK14 53 26 67 
AE1/AE3** 40 25 62 
CAM5.2 54 30 64 
MNF116 44 24 67 
34βE12 15 22 41 
CK7 33 36 49 
CK8 17 10 63 
CK18 18 12 60 
CK17 9 1 80 
CK19 18 26 41 
* The CKs used in this study were not uniformly tested in all cases; different combinations of 
CKs were used for each case; 
** Each pan-cytokeratin is considered as one CK antibody in this study. Other CKs including 
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Table 1b: Number of cytokeratin antibody combinations per case in the studied cohort 
(n=140).  
 
No. of CKs used per case No and (%) of cases 
1 6 (4)* 
2 10 (7) 
3 13 (9) 
4 36 (26) 
5 28 (20) 
6 18 (13) 
7 9 (7) 
8 10 (7) 
9 10 (7)** 
* 6 cases (out of 140) were tested for only one CK; 
** 10 cases (out of 140) were tested for a total of 9 CKs; 
In this study, 22 cases were negative with all the CKs they were tested for, whereas 43 cases 
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Table 1c: Number and percent (%) of cases positive or negative for the same number of CKs.  
 
No. of CKs 
No. and percent (%) of cases 
positive 
No. and percent (%) of cases 
negative 
1 19 (14)* 30 (21)** 
2 22 (16) 17 (12) 
3 29 (21) 17 (12) 
4 21 (15) 8 (6) 
5 12 (8) 10 (7) 
6 10 (7) 5 (4) 
7 4 (3) 5 (4) 
8 1 (1) 2 (1) 
9 0(0) 3 (2) 
* 19 cases (out of 140) were positive for 1 CK only regardless of the number of CKs tested 
per case 
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Table 2a: Correlation between the number of negative cytokeratins (CKs) and the total 
number of CKs requested – first half of the table - and the number of positive CKs – second 
half of the table (p<0.001).  
 
 Number of cases distributed by number of negative CK 
immunostains Total 
0~ 1 2 3 4 5 6 7 8 9 
Total no. of CK immunostains  
1 6* 0         6 
2 6 4 0        10 
3 6 4 0 2       12 
4 12 13 5 4 2      36 
5 7 5 6 2 2 6     28 
6 3 2 2 3 3 2 3    18 
7 2 1 0 1 0 0 1 4   9 
8 1 1 3 2 0 1 1 0 2  11 
   9** 0 0 1 3 1 1 0 1 0 3 10 
            
No. of positive CK immunostains  
0 0 0 0 2 2 6 3 4 2 3 22 
1 6* 4 0 4 2 2 1 0 0  19 
2 6 4 5 2 3 0 1 1   22 
3 6 13 6 3 0 1 0    29 
4 12 5 2 1 0 1     21 
5 7 2 0 2 1      12 
6 3 1 3 3       10 
7 2 1 1        4 
8 1 0         1 
Total 43 29 17 17 9 10 5 5 2 3 140 
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* 6 cases were stained with only 1 CK and they were all positive. 
** 9 CK antibodies were used in 10 cases: 3 were negative for all of the 9 CKs, 1 was 
negative for 7 CKs and positive for 2 CKs, 1 case was positive for 5 CKs and negative for 4, 
whereas 3 cases were positive for 3 CKs and negative for the remaining 6 CKs. 
Distribution of the number of negative CKs in the 22 cases that did not show any positivity 
for any of the tested CKs is highlighted in bold. The table shows that all CK negative MBC 
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Table 2b: Correlation between the number of negative cytokeratins (CKs) and the presence 
of associated adenocarcinomatous component and/or DCIS. 
 
Number of total CKs 
tested 
Number of cases distributed by number of negative 
CKs Total 
0 1 2 3 4 5 6 7 8 9 
No carcinomatous 
component 

















Figure 1A: This case with spindle cell morphology showed very focal CK expression: H&E (A), 
CK AE1/AE3 (B), CK5/6 (C), and p63 (D). In this case, p63 positivity was used in conjunction 






Figure 1B: This MBC showed a heterogeneous appearance (A) with squamous cell 









Figure 2: This case of malignant spindle cell lesion showed no evidence of carcinomatous 
differentiation and it was negative for all CKs tested (A, B). Reviewing the previous 
carcinoma in the same breast (C, D) revealed MBC with both squamous areas and spindle 
cell areas which were similar to those seen in the recurrences. The primary tumour was not 
tested for CKs due to the presence of squamous areas. In the recurrence, no such squamous 








Figure 3: This case showed an initial fibromatosis-like MBC (A) with CK5/6 positivity (B). 
Three years later the patient developed an axillary metastasis (C), which tested negative for 
CK5/6, CK14 (D), AE1/3, CAM5.2 and p63. Multiple metastatic deposits (digestive and 
paraspinal) developed after another 2 years and all showed similar spindle cell morphology 






Figure 4: This case presented as an ossifying lesion of the breast initially catalogued as 
ossifying fasciitis; morphologically it presented with woven bone and osteoid trabeculae 
lined by florid osteoblastic proliferation with scattered osteoclasts and focally loose stroma 
featuring a proliferation of non-atypical fibroblast-like cells – no CK expression was 






4 years later a bone metastasis was identified with similar features, however this time the 







Figure 5: This case was a malignant spindle cell tumour of the breast infiltrating the deep 
skeletal muscle; although no CK expression, DCIS or conventional invasive carcinoma were 
identified, it was defaulted to CK-MBC, after other lesions were excluded (DFSP, malignant 
melanoma, lymphoma, malignant phyllodes tumour). The lesion was negative for CD34 and 






Figure 6 – Diagnostic algorithm used in our department. 
MBC – metaplastic breast carcinoma; CK – cytokeratin; PT- phyllodes tumour.  
 
